max-40279
Small moleculeexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2018 (NCT03412292)
Timeline
Indications
Mechanism of action
FLT3 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
COC1=CC(F)=CC=C1C2=C(C)SC3=CN=C(NC4=CN(N=C4)C5CCNCC5)N=C23- Mol. weight
- 438.521 g/mol
Oral
No
Parenteral
No
Topical
No
Sources
- NCATSDL772G3NN7 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05395780 | Phase 2 | Jun 30, 2022 | Maxinovel Pty., Ltd. |
| NCT03412292 | Phase 1 | Jun 1, 2018 | Maxinovel Pty., Ltd. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Maxinovel Pty., Ltd. | For profit | 2 | 2 | 2 | 2018 |
1 organizations
Page 1 / 1